{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:17:35Z","timestamp":1787887055364,"version":"build-2784847793"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18676-w","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:38:38Z","timestamp":1762364318000},"page":"2056-2064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term Oncologic Outcomes Following Pathologic Complete Response for Esophageal Cancer"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-6451","authenticated-orcid":false,"given":"Andrew J.","family":"Sinnamon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir H.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan A. Lima","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutika","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaffer R. S.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.","family":"Lauwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Frakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hoffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobelle J.","family":"Baldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P.","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Pimiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"22","key":"18676_CR1","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med."},{"issue":"4","key":"18676_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2409408.","journal-title":"N Engl J Med."},{"issue":"4","key":"18676_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422. https:\/\/doi.org\/10.6004\/jnccn.2023.0019.","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"18676_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med."},{"key":"18676_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrab022","author":"M de Jongh","year":"2021","unstructured":"de Jongh M, Eyck BM, van der Werf LR, et al. Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. BJS Open. 2021. https:\/\/doi.org\/10.1093\/bjsopen\/zrab022.","journal-title":"BJS Open"},{"issue":"7","key":"18676_CR6","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.21037\/jtd.2018.06.85","volume":"10","author":"T Soror","year":"2018","unstructured":"Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis. 2018;10(7):4069\u201376. https:\/\/doi.org\/10.21037\/jtd.2018.06.85.","journal-title":"J Thorac Dis."},{"issue":"2","key":"18676_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/jso.24808","volume":"117","author":"AU Blackham","year":"2018","unstructured":"Blackham AU, Naqvi HSM, Schell MJ, et al. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2018;117(2):150\u20139. https:\/\/doi.org\/10.1002\/jso.24808.","journal-title":"J Surg Oncol"},{"issue":"3","key":"18676_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390. https:\/\/doi.org\/10.1245\/s10434-007-9747-3.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"18676_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","volume":"17","author":"X Xue","year":"2017","unstructured":"Xue X, Agalliu I, Kim MY, et al. New methods for estimating follow-up rates in cohort studies. BMC Med Res Methodol. 2017;17(1):155. https:\/\/doi.org\/10.1186\/s12874-017-0436-z.","journal-title":"BMC Med Res Methodol"},{"key":"18676_CR10","unstructured":"Putten W. V. (2004) Classification and regression tree analysis stata package. Rotterdam"},{"issue":"24","key":"18676_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"key":"18676_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003017","author":"T Shen","year":"2025","unstructured":"Shen T, Li T, Cao Y, Zhang Y, Li H. Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis. Int J Surg. 2025.\u00a0https:\/\/doi.org\/10.1097\/JS9.0000000000003017.","journal-title":"Int J Surg"},{"issue":"25","key":"18676_CR13","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.20.03611","volume":"39","author":"KA Goodman","year":"2021","unstructured":"Goodman KA, Ou FS, Hall NC, et al. Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J Clin Oncol. 2021;39(25):2803\u201315. https:\/\/doi.org\/10.1200\/JCO.20.03611.","journal-title":"J Clin Oncol"},{"issue":"11","key":"18676_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(23)00243-1.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18676-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:22Z","timestamp":1770899962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18676-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18676"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18676-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rutika Mehta reports being on the advisory board of BMS, Merck, Legend Biotech, Daiichi Sankyo, Glaxo SmithKline, Astellas, Amgen, and AstraZeneca; consulting for Jazz Pharmaceuticals; and DSMB of Arcus Biosciences. Jose Pimiento reports consulting for AstraZeneca, Ferronova, Johnson And Johnson Worldwide, and Alcresta. Shaffer Mok reports consulting for Steris and Amgen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}